Here is a fascinating picture from the Wall Street Journal, showing how much Medicare has been spending on hepatitis C treatments lately. You can see that the cost is rising dramatically:
Keep in mind, however, that the new and expensive hepatitis C treatments currently on the market will dramatically reduce costs in the future, because they are curing people of this chronic disease, and therefore preventing liver failure and even liver transplantation. In other words –money well spent!
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.